ArticleTransplantation direct2025
The Impact of Posttransplant Lymphoproliferative Disease in High-risk Kidney Transplant Recipients: Benefits of Prevention.
Article in Transplantation direct, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Posttransplant lymphoproliferative disease (PTLD) is increased in kidney transplant recipients who are Epstein-Barr virus (EBV) nonimmune (R Methods: A Markov model was created to quantify remaining patient life years (LYs) and quality-adjusted LYs (QALYs) in EBV D Results: A baseline 40-y-old EBV D Conclusions: PTLD has a significant impact on survival in high-risk kidney transplant recipients. Preventive strategies may be cost-effective but would depend on the degree of effectiveness, safety, and cost.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.